1. Academic Validation
  2. Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1): challenging target for antitubercular drug discovery

Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1): challenging target for antitubercular drug discovery

  • Chem Cent J. 2018 Jun 23;12(1):72. doi: 10.1186/s13065-018-0441-2.
Jineetkumar Gawad 1 Chandrakant Bonde 2
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Chemistry, SVKM's NMIMS School of Pharmacy & Technology Management, Shirpur Dist, Dhule, Maharashtra, 425 405, India. [email protected].
  • 2 Department of Pharmaceutical Chemistry, SVKM's NMIMS School of Pharmacy & Technology Management, Shirpur Dist, Dhule, Maharashtra, 425 405, India.
Abstract

Tuberculosis has proved harmful to the entire history of mankind from past several decades. Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1) is a recent target which was identified in 2009 but unfortunately it is neither explored nor crossed phase II. In past several decades few targets were identified for effective antitubercular drug discovery. Resistance is the major problem for effective antitubercular drug discovery. Arabinose is constituent of mycobacterium cell wall. Biosynthesis of arabinose is FAD dependant two step epimerisation reaction which is catalysed by DprE1 and DprE2 flavoprotein enzymes. The current review is mainly emphases on DprE1 as a perspective challenge for further research.

Keywords

Antitubercular agents; Covalent and non covalent inhibitors; DprE1; Future needs.

Figures